Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 350 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Encorafenib July 3, 2026 FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... November 15, 2022 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Acalabrutinib E-cigarettes: what we know and what we don’t March is Colon Cancer Awareness Month NCI and CRUK Take on Cancer’s Toughest Problems
